Vibrio cholerae O1, a causative agent of cholera, continues to be a major cause of illness and death especially in developing countries [7] . Since 1970 when the first appearance of V. cholerae O1 was reported, Cote d'Ivoire has had an evolving cholera epidemic. Several outbreaks occurred in 1983, 1989, 1991, 1994 and 2006 successively. Over 45% of the V. cholerae strains were resistant to ampicillin since 1991 and the resistance remained generally high until 2006 with 91.3%. High resistance to cotrimoxazole appeared in 1995 with 56.3% and again in 2006 [2] . Antibiotics are commonly administered as part of the treatment regimen; however, an increase in resistant strains of V. cholerae has developed in several countries [6] . The objective of this study was to determine the antimicrobial susceptibility patterns of V. cholerae 01 isolated during the cholera epidemic outbreak in Abidjan during the dry season in 2011.
Between January and March 2011, stool specimens and rectal swab samples were collected from patients with acute diarrhea. All samples were plated onto thiosulfate citrate bile sucrose agar (TCBS) and nutritive agar alkaline and alkaline peptone broth and Mueller Kauffman broth. Species identification of V. cholerae was performed by standard microbiology methods. Serogrouping and serotyping using immune serum (antiserum Vibrio cholerae 01 Bio-Rad F-92430, Marnes la coquette, France) confirmed the diagnosis of cholera. Susceptibility testing was performed using the KirbyBauer agar diffusion method. Interpretative categories of resistance were determined according to the French Society of Microbiology Antibiogramm committee (CA-SFM 2010). Quality control was performed with the reference strain E. coli ATCC 25922.
Out of 192 samples, 29 (15.1%) were positive for V. cholerae O1. All isolates belonged to the Ogawa serotype. Cotrimoxazole resistance was highest with 79.3% followed by tetracycline with 24.1%. For ampicillin, the resistance rate was 20.7%. Ciprofloxacin had the lowest resistance rate of 6.9%. Chloramphenicol and ampicillin showed intermediate resistance of 44.8% and 34.5% respectively (Table  1) . Resistance to at least three families of antibiotics defining multidrug resistance was found in 51.7% of isolates. The most frequent resistance pattern was AmSxtChl with 17.2%. Resistance to cotrimoxazole (SXT) was always associated with other antibiotics (Table 2) .
High resistance to cotrimoxazole has been reported in several countries in Africa. In Zambia, Mozambique and Senegal, resistance rates were 97%, 96.6% and 90.3% respectively [4, 5, 6] . In Côte d'Ivoire, during the 2006 cholera epidemic outbreak, all strains were resistant to cotrimoxazole. However, since 1995, there has been an increase in the rate of resistance to cotrimoxazole, from 56.3% to 100% in 2006 [2] . Previous use of cotrimoxazole prophylaxis [2] . It should be noted that since 2006, this molecule had been given to patients regularly. These data suggest that ciprofloxacin can still be used as a first-line treatment for cholera in this country. The high rate of MDR (51.7%) may be related to MDR strain emergence around the world including Madagascar [8] . This suggests that cotrimoxazole should not be used empirically in cholera treatment.
In conclusion, continuous surveillance with regard to drug resistance may help in the choice of a standardized scheme of treatment. Further genotypic characterization of Vibrio cholerae O1 isolates will be required.
